HeimPTKFF • OTCMKTS
add
Kalbe Farma Tbk PT
Við síðustu lokun
0,095 $
Árabil
0,087 $ - 0,11 $
Markaðsvirði
68,91 bn IDR
Meðalmagn
62,00
V/H-hlutf.
-
A/V-hlutfall
-
Aðalkauphöll
IDX
Viðskiptafréttir
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
| (IDR) | sep. 2024info | Breyting á/á |
|---|---|---|
Tekjur | 7,91 bn | 7,16% |
Rekstrarkostnaður | 2,29 bn | 15,55% |
Nettótekjur | 573,28 ma. | 6,97% |
Hagnaðarhlutfall | 7,25 | -0,14% |
Hagnaður á hvern hlut | 12,41 | 7,73% |
EBITDA | 874,81 ma. | 1,14% |
Virkt skatthlutfall | 23,01% | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
| (IDR) | sep. 2024info | Breyting á/á |
|---|---|---|
Reiðufé og skammtímafjárfestingar | 4,32 bn | 45,45% |
Heildareignir | 28,75 bn | 5,78% |
Heildarskuldir | 4,84 bn | 0,67% |
Eigið fé alls | 23,91 bn | — |
Útistandandi hlutabréf | 46,15 ma. | — |
Eiginfjárgengi | 0,00 | — |
Arðsemi eigna | 6,15% | — |
Ávöxtun eigin fjár | 7,16% | — |
Peningaflæði
Breyting á handbæru fé
| (IDR) | sep. 2024info | Breyting á/á |
|---|---|---|
Nettótekjur | 573,28 ma. | 6,97% |
Handbært fé frá rekstri | 1,16 bn | 22,56% |
Reiðufé frá fjárfestingum | -176,64 ma. | 33,78% |
Reiðufé frá fjármögnun | -421,11 ma. | 51,91% |
Breyting á handbæru fé | 481,86 ma. | 1.978,42% |
Frjálst peningaflæði | 752,00 ma. | 13,84% |
Um
PT Kalbe Farma Tbk, or simply known as Kalbe, is an Indonesian pharmaceutical, healthcare and nutrition company established in 1966. The company has expanded by strategic acquisitions of pharmaceutical companies, becoming an integrated consumer health and nutrition enterprise.
The Kalbe Group has brands in the prescription drugs, OTC drugs, energy drink and nutrition products, distribution arm that reaches over 1 million outlets. Notably, the company produces misoprostol, a drug which is used to treat stomach ulcers but is also widely used in Indonesia as an illegal abortifacient.
Company brands in healthcare and pharmaceutical segments include Promag, Mixagrip, Woods, Komix, Prenagen, Extra Joss and Fitbar.
Kalbe is the largest publicly listed pharmaceutical company in Southeast Asia with around US$5 billion in market capitalization and revenues of over Rp 15 trillion. Wikipedia
Stofnsett
10. sep. 1966
Vefsvæði
Starfsfólk
12.924
